Mon, Jun 15 02:31 PM

Intellia presents Phase 3 results for HAE gene therapy lonvo-z

Investing.com•Sat, Jun 13, 2026, 11:38 AM•2 min read

Developing story — details emerging. Check the source link for the latest updates.

Source: [Investing.com](https://www.investing.com/news/company-news/intellia-presents-phase-3-results-for-hae-gene-therapy-lonvoz-93CH-4741029)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Investing.com ↗

#finance #intellia #presents #phase #results #hae #gene #therapy #lonvo

More Headlines

FinanceSeeking Alpha• 6m ago

General Dynamics: Impressive Results, Challenging Risk/Reward

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 10m ago

Caterpillar: A World-Class Industrial At A World-Class Price Tag

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 13m ago

Kevin Warsh, The Fed's New Era, And The Trimmed Mean Debate

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 19m ago

Advantest: Favorable Short-To-Long-Term Outlook

Developing story — details emerging. Check the source link for the latest updates.

FinanceSeeking Alpha• 23m ago

Credit Acceptance: The 6% Workforce Reduction Is A Warning Sign

Developing story — details emerging. Check the source link for the latest updates.

FinanceBloomberg Markets• 24m ago

Europe’s Alternative to Patriot Missile Is Finding More Buyers

More nations are evaluating the European-made SAMP/T NG missile defense system, demonstrating the Franco-Italian interceptor’s emergence as an alternative to hard-to-get Patriot batteries from the US.